Soheila Safarpour
Research Subjects
Research Interests
Soheila Safarpour has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Ali Akbar Moghadamnia
Pharmaceutical Sciences Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran
1 shared publication - Anahita Ebrahimpour
Cellular and Molecular Biology Research Center
1 shared publication - Fateme Madani
Student Research Committee
1 shared publication - Fatemeh Shirafkan
Institute of Pharmacology, Biochemical Pharmacological Center, University of Marburg, 35043 Marburg, Germany
1 shared publication - Marzieh Pirzadeh
Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
1 shared publication - Seyed Mohammad Hosseini
Department of Pathology, Babol Branch, Islamic Azad University, Babol, Iran
1 shared publication
Latest Publications
- Open Access
- 1 January 2022
- Published by Wiley in BioMed Research International
- Vol. 2022 (1) , 2273000
Protective Effect of Kaempferol and Its Nanoparticles on 5‐Fluorouracil‐Induced Cardiotoxicity in Rats
Background. Fluorouracil (5‐FU) is the third most common chemotherapeutic agent used in the treatment of solid tumors. 5‐FU‐associated cardiotoxicity ranks the second causes of cardiotoxicity induced by chemotherapeutic drugs after anthracyclines. Kaempferol (KPF), a common flavonoid, possessing anti‐inflammatory, antiapoptotic, antioxidative properties, and its protective effects on cardiovascular disease has been reported in various studies. The current study is aimed at appraising the effect of KPF and KPF nanoparticles (NPs) on 5‐FU‐induced cardiotoxicity in rats. Methods. Thirty Male Wistar rats were divided into five groups as follows: control, 5‐FU, 5‐FU+10 mg/kg vitamin C, 5‐FU+ 1 mg/kg KPF, and 5‐FU+ 1 mg/kg KPF‐NPs. Cardiotoxicity was induced with an intraperitoneal injection of a single dose of 5‐FU (100 mg/kg). The control group received normal saline, and the treatment groups received KPF and KPF‐NPs with an intraperitoneal injection for 14 days. Each heart histopathological lesions were given a score of 0 to 3 in compliance with the articles for statistical analysis. Results. 5‐FU resulted in a significant cardiotoxicity represented by an increase in cardiac enzymes, MDA (malondialdehyde) levels, COX‐2 (cyclooxygenase‐2) expression, and histopathological degenerations. 5‐FU treatment also decreased body weight, TAC (total antioxidant capacity) values, VEGF (vascular endothelial growth factor) expression, blood cells, and hemoglobin (Hb) levels. Treatment with KPF and KPF‐NPs reduced oxidative stress, cardiac enzymes, COX‐2 expression, and VEGF expression. The number of blood cells, Hb levels, and histopathological degenerations, in cardiac tissue also body weight of animals, increased, followed by treatment with KPF and KPF‐NPs. Conclusion. Our results demonstrated that treatment with KPF and KPF‐NPs significantly improved cardiotoxicity induced by 5‐FU in rats.
- 1 January 2022
- Published by Wiley in BioMed Research International
- Vol. 2022 (1) , 2273000
Open AccessProtective Effect of Kaempferol and Its Nanoparticles on 5‐Fluorouracil‐Induced Cardiotoxicity in Rats
Background. Fluorouracil (5‐FU) is the third most common chemotherapeutic agent used in the treatment of solid tumors. 5‐FU‐associated cardiotoxicity ranks the second causes of cardiotoxicity induced by chemotherapeutic drugs after anthracyclines. Kaempferol (KPF), a common flavonoid, possessing anti‐inflammatory, antiapoptotic, antioxidative properties, and its protective effects on cardiovascular disease has been reported in various studies. The current study is aimed at appraising the effect of KPF and KPF nanoparticles (NPs) on 5‐FU‐induced cardiotoxicity in rats. Methods. Thirty Male Wistar rats were divided into five groups as follows: control, 5‐FU, 5‐FU+10 mg/kg vitamin C, 5‐FU+ 1 mg/kg KPF, and 5‐FU+ 1 mg/kg KPF‐NPs. Cardiotoxicity was induced with an intraperitoneal injection of a single dose of 5‐FU (100 mg/kg). The control group received normal saline, and the treatment groups received KPF and KPF‐NPs with an intraperitoneal injection for 14 days. Each heart histopathological lesions were given a score of 0 to 3 in compliance with the articles for statistical analysis. Results. 5‐FU resulted in a significant cardiotoxicity represented by an increase in cardiac enzymes, MDA (malondialdehyde) levels, COX‐2 (cyclooxygenase‐2) expression, and histopathological degenerations. 5‐FU treatment also decreased body weight, TAC (total antioxidant capacity) values, VEGF (vascular endothelial growth factor) expression, blood cells, and hemoglobin (Hb) levels. Treatment with KPF and KPF‐NPs reduced oxidative stress, cardiac enzymes, COX‐2 expression, and VEGF expression. The number of blood cells, Hb levels, and histopathological degenerations, in cardiac tissue also body weight of animals, increased, followed by treatment with KPF and KPF‐NPs. Conclusion. Our results demonstrated that treatment with KPF and KPF‐NPs significantly improved cardiotoxicity induced by 5‐FU in rats.